All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
The MDS Hub is pleased to present a visual abstract representing key data from a phase II clinical trial (NCT03383575) evaluating enasidenib, both in combination with azacitidine and as monotherapy in patients with high-risk IDH2-mutated MDS. The safety and efficacy of enasidenib has been previously reported by the MDS Hub.
To download this visual abstract, click below.Download here
Safety and efficacy of enasidenib in IDH2-mutated myelodysplastic syndrome
Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor approved by the U.S. Food and Drug Administration in 2017 for treating adult patients with relapsed/refractory...
What is the benefit of adding pevonedistat to azacitidine in patients with high-risk MDS or AML?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the MDS Hub was delighted to speak to Lionel Ades, Saint-Louis Hospital, Paris,...
Subscribe to get the best content related to MDS delivered to your inbox